DYNAMICS OF ADROPIN AND IRISIN BIOMARKERS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND TYPE 2 DIABETES MELLITUS
DOI:
https://doi.org/10.11603/1811-2471.2022.v.i2.12875Keywords:
biomarkers, energy metabolism, myocardial infarction, diabetes mellitusAbstract
summary. A pressing concern of modern medicine is the search for new biomarkers that can influence the development and course of acute myocardial infarction (AMI) in patents with type 2 diabetes mellitus (DM).
The aim – To examine the dynamics of adropin and irisin serum levels in diabetic patients with or without AMI complications.
Materials and Methods. In total, 134 AMI patients were enrolled. Among 60 examined AMI patients (group I), 41 patients were identified without early cardiovascular (CV) complications of AMI and 19 patients – with complicated AMI. Among 74 AMI patients with type 2 DM (group II), there were 48 patients without early AMI complications and 26 patients with early AMI complications. The control group consisted of 20 otherwise healthy persons. Serum levels of adropin and irisin were measured by enzyme-linked immunosorbent assay.
Results. The adropin and irisin serum levels on day 1 of treatment was low in both nondiabetic (I) and diabetic patients (II) compared with those in the control group (p<0.05). On the 10th day of treatment, the levels of adropin in group II patients without early AMI complications were reduced by 13.91 % compared with those in group I (p<0.05). Group II with the presence of early AMI complications showed a reduction of 17.34 % in adropin levels on day 10 compared with group II (p<0.05). On day 10 of treatment, the irisin levels in group II without early AMI complications were reduced by 18.94 % compared with those in group I (p<0.05). In group II with the presence of early AMI complications on the 10th day, the irisin levels were reduced by 23.87 % compared with those in group I (p<0.05).
Conclusions. The concentrations of adropin and irisin were significantly low in group II on day 1 and 10 of hospital stay. In the dynamics of treatment on day 10, the levels of adropin and irisin remained low in group II with early CV complications of AMI.
References
WHO Newsletter: 10 leading causes of death in the world. December 9, 2020. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death.
Cho, N.H., Shaw, J.E., Karuranga, S., Huang, Y., da Rocha Fernandes, J.D., Ohlrogge, A.W., & Malanda, B. (2018). IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice, 138, 271-281. DOI: 10.1016/j.diabres.2018. 02.023.
Standl, E., Khunti, K., Hansen, T.B., & Schnell, O. (2019). The global epidemics of diabetes in the 21st century: Current situation and perspectives. European Journal of Preventive Cardiology, 26(2), 7-14. DOI: 10.1177/ 2047487319881021.
WHO Newsletter: Diabetes. November 10, 2021. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/diabetes.
Echouffo-Tcheugui, J.B., Kolte, D., Khera, S., Aronow, H.D., Abbott, J.D., Bhatt, D.L., & Fonarow, G.C. (2018). diabetes mellitus and cardiogenic shock complicating acute myocardial infarction. The American Journal of Medicine, 131(7), 778-786. DOI: 10.1016/j.amjmed.2018.03.004.
Khalid, S.H., Liaqat, I., Mallhi, T.H., Khan, A.H., Ahmad, J., & Khan, Y.H. (2020). Impact of diabetes mellitus on clinico-laboratory characteristics and in-hospital clinical outcomes among patients with myocardial infarction. JPMA. The Journal of the Pakistan Medical Association, 70(12(B)), 2376-2382. DOI: 10.47391/JPMA.370.
Jasaszwili, M., Billert, M., Strowski, M.Z., Nowak, K.W., & Skrzypski, M. (2020). Adropin as a fat-burning hormone with multiple functions-review of a decade of research. Molecules (Basel, Switzerland), 25(3), 549. DOI: 10.3390/molecules25030549.
Anastasilakis, A.D., Koulaxis, D., Kefala, N., Polyzos, S.A., Upadhyay, J., Pagkalidou, E., …, & Mantzoros, C.S. (2017). Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism: Clinical and Experimental, 73, 1-8. DOI: 10.1016/j.metabol.2017. 05.002.
Ibanez, B., James, S., Agewall, S., Antunes, M.J., Bucciarelli-Ducci, C., Bueno, H., …, & ESC Scientific Document Group (2018). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 39(2), 119-177. DOI: 10.1093/eurheartj/ehx393.
Online version of IDF Diabetes Atlas: Nineth edition, 2019. Available at: https://www.diabetesatlas.org/en/.
Davies, M.J., D'Alessio, D.A., Fradkin, J., Kernan, W.N., Mathieu, C., Mingrone, G., …, & Buse, J.B. (2018). Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 61(12), 2461-2498. DOI: 10.1007/s00125-018-4729-5.
Cosentino, F., Grant, P.J., Aboyans, V., Bailey, C.J., Ceriello, A., Delgado, V., …, & ESC Scientific Document Group. (2020). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 41(2), 255-323. DOI: 10.1093/eurheartj/ehz486.
Simek, S., Motovska, Z., Hlinomaz, O., Kala, P., Hromadka, M., Knot, J., …, & On Behalf Of The Prague-Study Group (2020). The effect of diabetes on prognosis following myocardial infarction treated with primary angioplasty and potent antiplatelet therapy. Journal of Clinical Medicine, 9(8), 2555. DOI: 10.3390/jcm9082555.
Koteliukh, M.Yu. (2021). Peculiarities of changes in the structural and functional state of the myocardium in patients with acute myocardial infarction and type 2 diabetes taking into account FABP 4 and CTRP 3. Zdobutki klinichnoyi i eksperimentalnoyi medicini – Achievements of Clinical and Experimental Medicine, 4, 21-28. DOI: 10.11603/1811-2471.2021.v.i4.12668.
Zheng, J., Liu, M., Chen, L., Yin, F., Zhu, X., Gou, J., …, & Lv, Z. (2019). Association between serum adropin level and coronary artery disease: a systematic review and meta-analysis. Cardiovascular Diagnosis and Therapy, 9(1), 1-7. DOI: 10.21037/cdt.2018.07.09.
Yu, H.Y., Zhao, P., Wu, M.C., Liu, J., & Yin, W. (2014). Serum adropin levels are decreased in patients with acute myocardial infarction. Regulatory Peptides, 190-191, 46-49. DOI: 10.1016/j.regpep.2014.04.001.
Wang, B., Xue, Y., Shang, F., Ni, S., Liu, X., Fan, B., & Wang, H. (2019). Association of serum adropin with the presence of atrial fibrillation and atrial remodeling. Journal of Clinical Laboratory Analysis, 33(2), e22672. DOI: 10.1002/jcla.22672.
Aşkın, L., Aşkın, H.Ş., Tanrıverdi, O., & Hoşoğlu, Y. (2022). Serum adropin: pathogenesis and clinical research in cardiovascular disease. Erciyes Med. J., 44(1), 8-11. DOI: 10. 14744/etd.2021.23571.
Kalkan, A.K., Cakmak, H.A., Erturk, M., Kalkan, K.E., Uzun, F., Tasbulak, O., …, & Celik, A. (2018). Adropin and irisin in patients with cardiac cachexia. Arquivos Brasileiros de Cardiologia, 111(1), 39-47. DOI: 10.5935/abc.20180109.
Khorasani, Z.M., Bagheri, R.K., Yaghoubi, M.A., Chobkar, S., Aghaee, M.A., Abbaszadegan, M.R., & Sahebkar, A. (2019). The association between serum irisin levels and cardiovascular disease in diabetic patients. Diabetes & Metabolic Syndrome, 13(1), 786-790. DOI: 10.1016/j.dsx. 2018.11.050.
Aydin, S., Aydin, S., Kobat, M.A., Kalayci, M., Eren, M.N., Yilmaz, M., …, & Baydas, A. (2014). Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology. Peptides, 56, 141-145. DOI: 10.1016/ j.peptides.2014.04.002.
Berezin, A.E., Berezin, A.A., & Lichtenauer, M. (2021). Myokines and heart failure: challenging role in adverse cardiac remodeling, myopathy, and clinical outcomes. Disease Markers, 2021, 6644631. DOI: 10.1155/2021/ 6644631.
Abd El-Mottaleb, N.A., Galal, H.M., El Maghraby, K.M., & Gadallah, A.I. (2019). Serum irisin level in myocardial infarction patients with or without heart failure. Canadian Journal of Physiology and Pharmacology, 97(10), 932-938. DOI: 10.1139/cjpp-2018-0736.
Anaszewicz, M., Wawrzeńczyk, A., Czerniak, B., Banaś, W., Socha, E., Lis, K., …, & Budzyński, J. (2019). Leptin, adiponectin, tumor necrosis factor α, and irisin concentrations as factors linking obesity with the risk of atrial fibrillation among inpatients with cardiovascular diseases. Kardiologia Polska, 77(11), 1055-1061. DOI: 10.33963/KP.14989.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
